A detailed history of Black Rock Inc. transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Black Rock Inc. holds 270,064 shares of AMRN stock, worth $124,229. This represents 0.0% of its overall portfolio holdings.

Number of Shares
270,064
Previous 249,710 8.15%
Holding current value
$124,229
Previous $222,000 16.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.63 - $1.07 $12,823 - $21,778
20,354 Added 8.15%
270,064 $186,000
Q1 2024

May 10, 2024

BUY
$0.82 - $1.35 $41,533 - $68,377
50,650 Added 25.44%
249,710 $222,000
Q4 2023

Feb 13, 2024

SELL
$0.66 - $0.91 $17,821 - $24,572
-27,003 Reduced 11.94%
199,060 $173,000
Q3 2023

Nov 13, 2023

SELL
$0.85 - $1.43 $45,078 - $75,837
-53,033 Reduced 19.0%
226,063 $207,000
Q2 2023

Aug 11, 2023

SELL
$1.12 - $1.49 $25,226 - $33,560
-22,524 Reduced 7.47%
279,096 $332,000
Q1 2023

May 12, 2023

SELL
$1.19 - $2.19 $20,791 - $38,263
-17,472 Reduced 5.48%
301,620 $452,000
Q4 2022

Feb 13, 2023

SELL
$1.07 - $1.34 $43,521 - $54,503
-40,674 Reduced 11.31%
319,092 $386,000
Q3 2022

Nov 14, 2022

BUY
$1.09 - $1.67 $95,783 - $146,751
87,875 Added 32.32%
359,766 $392,000
Q2 2022

Aug 12, 2022

BUY
$1.13 - $3.69 $67,432 - $220,200
59,675 Added 28.12%
271,891 $404,000
Q1 2022

May 12, 2022

BUY
$2.85 - $3.73 $21,169 - $27,706
7,428 Added 3.63%
212,216 $698,000
Q4 2021

Feb 10, 2022

BUY
$3.24 - $5.18 $22,748 - $36,368
7,021 Added 3.55%
204,788 $690,000
Q3 2021

Nov 09, 2021

BUY
$3.94 - $5.84 $122,581 - $181,694
31,112 Added 18.67%
197,767 $1.01 Million
Q2 2021

Aug 11, 2021

BUY
$4.26 - $6.5 $709,950 - $1.08 Million
166,655 New
166,655 $730,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $185M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.